Related Experiment Video
Updated: Aug 23, 2025
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
Biodegradable Carbon Dioxide-Derived Non-Viral Gene Vectors for Osteosarcoma Gene Therapy
Meirong Li1,2, Zheng-Ian Lin3, Jingyu Yang2
1Central Laboratory, The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen, Guangdong, 518172, P. R. China.
Abstract:
Osteosarcoma often occurs in children and adolescents with high invasiveness and high mortality. Polo-like kinase 1 (PLK1) overexpressed in most tumors promotes cancer cell proliferation and transformation. PLK1 is considered as a therapeutic target for osteosarcoma. RNA interference-based therapies are employed to combat osteosarcoma through silencing PLK1 gene expression. However, the treatment results remain unsatisfactory due to the lack of a safe and efficient nonviral gene vector. To tackle this hurdle, biodegradable and CO2 -derivative cationic poly(vinylcyclohexene carbonates) (CPCHCs) are used as gene vectors to perform a siPLK1 therapeutic strategy for osteosarcoma treatment. Of those CPCHCs, CPCHC60 demonstrates the most excellent performance in gene transfection efficiency, endo-lysosome escaping, biodegradability, and biosafety. With the treatment of CPCHCs/siRNA nanoparticles, the expression level of PLK1 gene in osteosarcoma cells is significantly down-regulated. Subsequently, cells are arrested in the G2 /M phase and subsequently dead in the form of apoptosis, resulting in significant tumor regression both in vitro and in vivo. This study brings a new insight into the development of superior nonviral gene vectors for practical cancer treatment. Based on the results, the resulting nanoparticle-based gene drug formation is considered to have a highly successful chance in further translational nanomedicine applications.
Insights
Biodegradable cationic poly(vinylcyclohexene carbonates) (CPCHCs) effectively deliver siRNA to silence Polo-like kinase 1 (PLK1) in osteosarcoma. This nanoparticle-based therapy inhibits tumor growth and induces apoptosis, offering a promising cancer treatment strategy.
Area of Science:
- Biomedical Engineering
- Nanomedicine
- Oncology
Background:
- Osteosarcoma presents a significant challenge in pediatric and adolescent oncology due to its high invasiveness and mortality.
- Polo-like kinase 1 (PLK1) is frequently overexpressed in tumors, driving cancer cell proliferation and transformation, making it a key therapeutic target.
- Current RNA interference therapies for osteosarcoma are limited by the lack of safe and efficient nonviral gene vectors.
Purpose of the Study:
- To develop and evaluate novel biodegradable cationic poly(vinylcyclohexene carbonates) (CPCHCs) as nonviral gene vectors for osteosarcoma treatment.
- To investigate the efficacy of CPCHCs in delivering small interfering RNA (siRNA) targeting PLK1 (siPLK1) for osteosarcoma therapy.
- To assess the safety and transfection efficiency of CPCHCs in preclinical osteosarcoma models.
Main Methods:
- Synthesis and characterization of CO2-derivative cationic poly(vinylcyclohexene carbonates) (CPCHCs) as gene vectors.
- Formulation of CPCHCs/siPLK1 nanoparticles for targeted gene delivery.
- In vitro evaluation of gene transfection efficiency, endo-lysosome escaping, biodegradability, and biosafety of CPCHCs.
- Assessment of PLK1 gene silencing, cell cycle arrest (G2/M phase), apoptosis induction, and tumor regression in osteosarcoma models (in vitro and in vivo).
Main Results:
- CPCHC60 exhibited superior performance in gene transfection, endo-lysosome escape, biodegradability, and biosafety compared to other CPCHCs.
- CPCHCs/siRNA nanoparticles significantly down-regulated PLK1 gene expression in osteosarcoma cells.
- Treatment induced G2/M phase cell cycle arrest and apoptosis, leading to substantial tumor regression in vitro and in vivo.
- The developed nanoparticle-based gene drug demonstrated excellent translational potential.
Conclusions:
- Biodegradable CPCHCs represent a highly effective and safe nonviral gene vector system for osteosarcoma therapy.
- siPLK1 delivery using CPCHCs nanoparticles offers a promising therapeutic strategy for osteosarcoma, targeting key oncogenic pathways.
- This study highlights the potential of CPCHCs in advancing nanomedicine for practical cancer treatment applications.
